Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).

Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama K, Azuma J, Ogihara T, Saruta T, Nakao K; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.

Contemp Clin Trials. 2009 Jan;30(1):97-101. doi: 10.1016/j.cct.2008.09.006. Epub 2008 Sep 13.

PMID:
18824134
2.

Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).

Ogihara T, Ueshima K, Nakao K, Fukiyama K, Oba K, Yasuno S, Fujimoto A, Sato T, Matsuoka H, Saruta T; CASE-J Ex Study Group.

Hypertens Res. 2011 Dec;34(12):1295-301. doi: 10.1038/hr.2011.120. Epub 2011 Aug 11.

PMID:
21833000
3.

ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.

Ogihara T, Fujimoto A, Nakao K, Saruta T; CASE-J Trial Group.

Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1195-201. doi: 10.1586/14779072.6.9.1195.

PMID:
18939907
4.

[Clinical implications from the results of the CASE-J extension].

Yasuno S, Fujimoto A, Ueshima K.

Nihon Rinsho. 2012 Mar;70(3):519-27. Japanese.

PMID:
22514936
5.

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.

Hypertension. 2008 Feb;51(2):393-8. doi: 10.1161/HYPERTENSIONAHA.107.098475. Epub 2008 Jan 2.

PMID:
18172059
6.

Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.

Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K; CASE-J Study Group.

Hypertens Res. 2009 Jun;32(6):505-12. doi: 10.1038/hr.2009.44. Epub 2009 Apr 24. Erratum in: Hypertens Res. 2009 Dec;32(12):1157.

PMID:
19390535
7.

Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.

Nakao K, Hirata M, Oba K, Yasuno S, Ueshima K, Fujimoto A, Ogihara T, Saruta T; CASE-J Trial Group.

Hypertens Res. 2010 Jun;33(6):600-6. doi: 10.1038/hr.2010.38. Epub 2010 Apr 9.

PMID:
20379187
8.

Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).

Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S; J-RHYTHM II Investigators.

Europace. 2011 Apr;13(4):473-9. doi: 10.1093/europace/euq439. Epub 2010 Dec 10.

PMID:
21148662
9.

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.

Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, Fukushima M, Sakamoto J, Morita S, Ogihara T, Fukiyama K, Fujishima M, Saruta T; CASE-J Study Group.

Hypertens Res. 2003 Dec;26(12):979-90. Review.

11.

Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.

Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K; OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.

Am J Med. 2012 Oct;125(10):981-90. doi: 10.1016/j.amjmed.2011.12.010. Epub 2012 Apr 14.

PMID:
22503610
12.

Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.

Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T.

Nephron Clin Pract. 2005;99(1):c18-23.

PMID:
15637459
13.

Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).

Yamaguchi J, Hagiwara N, Ogawa H, Koyanagi R, Kasanuki H, Takagi A, Mori F, Nagashima M, Yagi M; HIJ-CREATE Investigators.

Am J Cardiol. 2010 Sep 15;106(6):819-24. doi: 10.1016/j.amjcard.2010.05.007. Epub 2010 Aug 2.

PMID:
20816122
14.

The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.

Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H, Saruta T; CASE-J Trial Group.

Hypertens Res. 2008 Aug;31(8):1595-601. doi: 10.1291/hypres.31.1595.

PMID:
18971535
16.

Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).

Maeda A, Tamura K, Kanaoka T, Ohsawa M, Haku S, Azushima K, Dejima T, Wakui H, Yanagi M, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, Umemura S.

Clin Exp Hypertens. 2012;34(4):249-57. doi: 10.3109/10641963.2012.681081. Epub 2012 May 9.

PMID:
22571446
17.

Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial.

Ueshima K, Yasuno S, Oba K, Fujimoto A, Ogihara T, Saruta T, Nakao K.

Circ J. 2009 Jun;73(6):1080-5. Epub 2009 Mar 12.

19.

Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.

Yasuno S, Ueshima K, Oba K, Fujimoto A, Hirata M, Ogihara T, Saruta T, Nakao K.

Diabetes Care. 2010 May;33(5):1122-7. doi: 10.2337/dc09-1447. Epub 2010 Feb 25.

20.

Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.

Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.

Hypertens Res. 2002 Nov;25(6):849-55.

Supplemental Content

Support Center